Floatz logo

Pembrolizumab

Smoldering Plasma Cell Myeloma

M.D. Anderson Cancer Centermonoclonal_antibodyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Smoldering Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Regeneron Pharmaceuticals
Phase 3BB
FILGRASTIM
Regeneron Pharmaceuticals
Phase 3BB
cc-5013
Irene Ghobrial, MD
Phase 3BB
Linvoseltamab
Regeneron Pharmaceuticals
Phase 3BB
DARATUMUMAB
Regeneron Pharmaceuticals
Phase 3BB

View all 48 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →